Associate Professor Martin Ng

Our mission is to identify unmet needs in interventional cardiology practice and provide innovative solutions to improve patient care.

Martin Ng is a physician-scientist and cardiologist. He is the leader of the Translational Research and Bioengineering Group, a unit he established after completing postdoctoral studies in the Biodesign Innovation Program at Stanford University. His mission was to ‘translate’ scientific discoveries at the lab bench into exciting new treatments for cardiovascular disease. Associate Professor Ng He is also an Interventional Cardiologist at the Royal Prince Alfred Hospital where he heads an internationally recognised team providing cutting-edge treatment of heart valve and coronary artery disease.

Current Appointments

Translational Research and Bioengineering Group Leader

Heart Research Institute

Senior Staff Specialist in Cardiology

Royal Prince Alfred Hospital

Conjoint Associate Professor of Medicine

University of Sydney

Associate Editor

Heart Lungand Circulation


National Health and Medical Research Council (NHMRC) Grant Review Committee

National Heart Foundation Grant Review Committee

National Health and Medical Research Council (NHMRC) Research Translation Faculty

Ad-hoc reviewer for multiple journals including Circulation & Am J Path
Scientific advisory board member


Abbott Vascular

St Jude

Associate Professor Martin Ng leads group:
Research covers areas of:
Contact Associate Professor Martin Ng
LinkedIn: View profile

More about Associate Professor Martin Ng

Research Project Opportunities
Collapse -
Expand +
The Role of Thioredoxin Interacting Protein in the Pathogenesis of Diabetic Vascular Complications

Endothelial damage, impaired endothelial regeneration and endothelial dysfunction play a critical role in the onset and progression of diabetic vascular complications. Chronic hyperglycemia is a major initiator of diabetic vascular complications. Thioredoxin Interacting Protein, or TXNIP, an exquisitely glucose-inducible gene, is a multi-functional protein that is emerging as a key regulator of endothelial biology. This project seeks to investigate the role of TXNIP in the pathogenesis of diabetic vascular complications, with a particular focus on the mechanisms by which TXNIP modulates diabetes-related susceptibility to endothelial damage and dysfunction.

The protective effects of fenofibrate in diabetes-related susceptibility to ischaemia

The vascular complications of diabetes are associated with impaired angiogenesis in response to ischaemia and impaired tolerance to hypoxia, though the mechanisms for this are poorly understood. The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) placebo-controlled randomised trial, led by our collaborator Professor Anthony Keech (NHMRC clinical trial centre) demonstrated for the first time that fenofibrate therapy in type 2 diabetes significantly and substantially reduced the risk of microvascular-related complications. This project seeks to investigate the effects of fenofibrate, a synthetic ligand for the peroxisome proliferated activated receptor alpha, on impaired ischaemia-mediated angiogenesis and hypoxia tolerance in diabetes mellitus.   

The Role of Androgens in Angiogenesis

While men are more likely to develop coronary artery disease than women, men are also more likely to have a favourable outcome after a heart attack compared to women. This gender difference after heart attacks, suggests that sex hormones such as the androgens, may play a role in the reparative response after a heart attack. In fact, there is evidence from some studies in cells and in animals that androgens increase blood vessel formation. We will study the effects of androgens on angiogenesis and in mobilising endothelial progenitor cells using human cells, animal studies and in a human clinical trial.   

Featured Publication
Collapse -
Expand +
L.L. Dunn, P.J. Simpson, H.C. Prosser, L. Lecce, G.S. Yuen, A. Buckle, D.P. Sieveking, L.Z. Vanags, P.R. Lim, R.W. Chow, Y.T. Lam, Z. Clayton, S. Bao, M.J. Davies, N. Stadler, D.S. Celermajer, R. Stocker, C.A. Bursill, J.P. Cooke, M.K. Ng, A critical role for thioredoxin-interacting protein in diabetes-related impairment of angiogenesis, Diabetes, 63 (2014) 675-687.

Vascular disease in diabetes is hallmarked by the development of impaired function of the endothelium, a critically important layer of cells that lines the blood vessel walls and serves to protect blood vessels from injury and disease. We found that high glucose levels in diabetes directly interfere with the regulation of a protein called Thioredoxin Interacting Protein, or TXNIP, one of the most glucose-sensitive genes in the entire human genome. By preventing high glucose-mediated interference with TXNIP, we were able to strikingly rescue the endothelial cell dysfunction of diabetes, with important implications for the development of new, more effective therapies.

Awards for research
Collapse -
Expand +
2011     Foundation of High Blood Pressure Research Colin Johnston Lecture, a lectureship awarded to a distinguished but relatively early career researcher, who serves as an inspiration to new investigators in the early postdoctoral period.
2010     Royal Prince Alfred Foundation Medal for excellence and outstanding achievement in medical research.
2006     For his invention of a platform conformable polymer technology for seal of endovascular implants, Dr Ng was awarded: First Place, Stanford University Biodesign Innovation Program and National Collegiate Inventors and Innovators Alliance of U.S. Advanced E-Team Award.
Current Research Grants
Collapse -
Expand +
National Health and Medical Research Council (NHMRC) Development Grant 1075357, Tissue Engineered Synthetic Vascular Grafts for Arterial Replacement, 2014-2015
National Health and Medical Research Council (NHMRC) Project Grant 1066174, Bioengineering Synthetic Elastin Conduits for Arterial Revascularisation, 2014-2016
National Health and Medical Research Council (NHMRC) Project Grant 1066541, Protective Effects of Fenofibrate in Diabetes-Related Susceptibility to Ischaemia, 2014-2016
University of Sydney Early Career Researcher Grant, Supporting Dr. Monica Lam, 2015
2005     Fellow of the Cardiac Society of Australia and New Zealand
2004     PhD, University of Sydney
2000     Fellow of the Royal Australasian College of Physicians
1993     Hons I, M.B.B.S, University of Sydney
Wise S.G. and Ng, M.K.C, “Medical Devices with Reduced Thrombogenicity”. US Provisional Patent Application U.S.S.N. 62/049,879. Filed September 12th, 2014.
Ng, M.K.C., Waterhouse A., Weiss, A.S. and Wise S.G., “Chemically and Biologically Modified Medical Devices”. Awarded US Patent no. 12/652926, Original filing 2009. Issued in the United States on August 19, 2014 – US Patent number 8,808,365.  
Ng, M.K.C., Weiss, A.S. and Wise S.G., “Tropoelastin-based Protoelastin Biomaterials”. Awarded US Patent no. 11/864006, Original filing 2007.  Issued in the United States on April 20, 2010 – US Patent number 7,700,126.